{"filing":{"accession_number":"0001193125-26-407293","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"d153773d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526407293/d153773d6k.htm"},"events":[{"id":35722,"run_id":32920,"accession_number":"0001193125-26-407293","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 210,812 ordinary shares at an average price of approximately USD $123.36 per share, increasing share capital by nominal DKK 210,812. This constitutes a dilutive equity issuance that would materially affect shareholder ownership and is reportable under Item 3.02 equivalent disclosure requirements for foreign private issuers.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":39882,"accession_number":"0001193125-26-407293","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 210,812 ordinary shares at an average price of approximately USD $123.36 per share, increasing share capital by nominal DKK 210,812. This constitutes a dilutive equity issuance that would materially affect shareholder ownership and is reportable under Item 3.02 equivalent disclosure requirements for foreign private issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:04:43.125405+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-29"}]}